Logo
Nazad
Blixt Lisa, Yu Gao, David Wullimann, Hanna Murén Ingelman-Sundberg, S. Muschiol, K. Healy, G. Bogdanovic, E. Pin, P. Nilsson, Christian Kjellander, A. Grifoni, A. Sette, Margaret Sällberg Chen, H. Ljunggren, M. Buggert, L. Hansson, A. Osterborg
7 23. 9. 2022.

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination

Conflict of interest: COI declared see note COI notes: The authors declare no competing financial interests. MB is a consultant for Oxford Immunotech. AS is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. Preprint server: No; Author contributions and disclosures: LB, LH, AÖ, GB, MSC, HGL and MB contributed to conceptualization, funding acquisition and discussion of data. YG, KH and SM and DW performed experiments and analyzed data. LB, HMIS, CK, LH and AÖ recruited study participants, conducted management of participants during the study and analyzed data. AG and AS provided peptide pools to measure the spike-specific T cell responses. LB, DW, AÖ, LH, HGL and MB wrote the original draft of the manuscript. All authors reviewed and edited revisions of the manuscript and had final responsibility for the decision to submit for publication. Non-author contributions and disclosures: No; Agreement to Share Publication-Related Data and Data Sharing Statement: Emails to the corresponding author Clinical trial registration information (if any):


Pretplatite se na novosti o BH Akademskom Imeniku

Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo

Saznaj više